Evrysdi
Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy
June 5, 2025Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)
Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
EC approves Roche’s Evrysdi for babies under two months with SMA
August 30, 2023Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy
Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …
Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy
August 10, 2020Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy
Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
